Lessons from Secretin

Publisher Website
Google Scholar
Abstract
In this issue of the Journal, Sandler and colleagues report the negative results of a double-blind, placebo-controlled trial of a single intravenous dose of synthetic human secretin in children with autism or pervasive developmental disorder.1 Autistic disorder is a serious neuropsychiatric disorder with onset in the first years of life that is characterized by delayed and deviant social and communication skills, associated with various forms of unusual behavior (e.g., repetitive behavior and unusual responses to the environment).2 The term pervasive developmental disorder not otherwise specified refers to a condition with symptoms suggestive of autism but that does not meet the . . .